藤梨根抗肿瘤药效物质和药理活性研究进展

doi:10.11904/j.issn.1002-3070.2022.01.013

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (1): 69-73.doi: 10.11904/j.issn.1002-3070.2022.01.013

藤梨根抗肿瘤药效物质和药理活性研究进展

孟鑫, 鲁金月, 张爱琳综述, 何录文审校

黑龙江中医药大学(哈尔滨 150040)

收稿日期:2021-01-29 修回日期:2021-04-27 出版日期:2022-02-28 发布日期:2022-01-21
通讯作者: 鲁金月,E-mail:lujinyue0630@163.com
作者简介:孟鑫,男,(1982-),博士,副教授,从事中药药效物质与质量标准的研究。
基金资助:
黑龙江中医药大学大学生科技创新项目(编号:2020-9);黑龙江中医药管理局项目(编号:ZHY18-021);黑龙江中医药大学大学生创新创业训练计划项目(编号:16041200075);黑龙江中医药大学科研基金项目(编号:2019MS27);黑龙江省大学生创新创业训练计划项目(编号:S202110228003)

Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis

MENG Xin, LU Jinyue, ZHANG Ailin, HE Luwen

Heilongjiang University of Chinese Medicine,Harbin 150040,China

Received:2021-01-29 Revised:2021-04-27 Online:2022-02-28 Published:2022-01-21

摘要/Abstract

摘要： 猕猴桃科猕猴桃属植物藤梨根是一味清热解毒类的传统中药,主要分布在我国东北地区,在华北、西北及长江流域也有少量分布。藤梨根因其广泛的抗肿瘤活性,引起国内外学者的密切关注。目前已从藤梨根中分离得到三萜类、黄酮类、蒽醌类、甾体类、生物碱类、苯丙素类等化学成分,且在胃癌、肠癌、食管癌、肝癌、肺癌、宫颈癌、卵巢癌、乳腺癌等恶性肿瘤中取得显著疗效。本文就藤梨根的抗肿瘤药效物质和药理活性作了较为详细的阐述,以期为藤梨根的深入研究及临床应用提供参考。

关键词: 藤梨根, 抗肿瘤, 药效物质, 药理活性

Abstract: The root of Radix Actinidia chinensis is a traditional Chinese medicine for clearing heat and detoxifying toxins,mainly in the northeast of China,with a small distribution in northern and northwestern China and the Yangtze River basin.The root has attracted close attention from scholars at home and abroad due to its extensive anti-tumor activity.At present,triterpenoids,flavonoids,anthraquinones,steroids,alkaloids,phenylpropanoids and other chemical components have been isolated from the root,and have achieved significant efficacy in malignant tumors such as gastric cancer,intestinal cancer,esophageal cancer,liver cancer,lung cancer,cervical cancer,ovarian cancer,breast cancer,etc.In this paper,the antitumour substances and pharmacological activities of Radix Actinidia chinensis are described in details,with a view to providing references for further research and clinical application of Radix Actinidia chinensis.

Key words: Radix Actinidia chinensis, Anti-tumor effects, Medicinal substance, Pharmacological activity

中图分类号:

孟鑫, 鲁金月, 张爱琳, 何录文. 藤梨根抗肿瘤药效物质和药理活性研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 69-73.

MENG Xin, LU Jinyue, ZHANG Ailin, HE Luwen. Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis[J]. Journal of Practical Oncology, 2022, 36(1): 69-73.

参考文献

1 王群,李云秋.中华猕猴桃根化学成分抗肿瘤作用的研究进展[J].华夏医学,2017,30(1):145-148.
2 陈方超,高守红,王志鹏,等.基于UHPLC-Q-TOF-MS/MS技术鉴定藤梨根的化学成分[J].中国药房,2020,31(14):1725-1731.
3 温庆伟,郑妮,陈春霞,等.阳桃根中化学成分类型的试验研究[J].中药与临床,2013,4(2):9-11.
4 Zhou XF,Zhang P,Pi HF,et al.Triterpenoids from the roots of actinidia chinensis[J].Chem Biodiversity,2009,6(8):1202-1207.
5 Wei LB,Ma SY,Liu HX,et al.Cytotoxic triterpenoids from roots of actinidia chinensis[J].Chem Biodiversity,2018,15(2):1-6.
6 张慧莹,王璇,丁婷婷,等.软枣猕猴桃根蒽醌类化合物的提取及其体外抗肿瘤实验[J].中国老年学杂志,2011,31(23):4630-4631.
7 Song WY,Xu GH,Zhang GJ.Effect of actinidia chinensis planch polysaccharide on the growth and apoptosis,and p-p38 expression in human gastric cancer SGC-7901 cells[J].Chin J Integr Med,2014,34(3):329-333.
8 王岚,康琛,杨伟鹏,等.藤梨根正丁醇提取物和总黄酮苷抗肿瘤作用研究[J].中国中药杂志,2010,35(16):2184-2186.
9 Cheng QL,Li HL,Huang ZQ,et al.2β,3β,23-trihydroxy-urs-12-ene-28-olic acid(TUA)isolated from Actinidia chinensis Radix inhibits NCI-H460 cell proliferation by decreasing NF-κB expression[J].Chem Biol Interact,2015,38(240):1-11.
10 Chang J,Case R.Cytotoxic constituents from the root of actinidia chinensis[J].Planta Med,2006,72(2):955-959.
11 Ku CY,Wang YR,Lin HY,et al.Corosolic acid inhibits hepatocellular carcinoma cell Migration by targeting the VEGFR2/Src/FAK pathway[J].PLoS One,2015,10(5):e0126725.
12 曹雯.胃康颗粒联合化疗对胃癌临床疗效的观察[D].南京:南京中医药大学,2020.
13 附舰,陈光伟,刘理礼,等.藤梨根提取物对人胃癌MKN-45细胞增殖及凋亡的影响[J].现代肿瘤医学,2011,19(1):20-22.
14 党辉,牟宗玲,宋锐,等.藤梨根提取物对人胃癌SGC7901细胞增殖抑制的影响[J].中国老年学杂志,2017,37(4):786-788.
15 徐楚韵,张光霁,楼招欢,等.藤梨根有效组分抑制胃癌BGC-823细胞增殖与迁移作用的研究[J].南京中医药大学学报,2018,34(6):602-606.
16 Zhou CX,Wang CL,Yu AL,et al.MiR-630 suppresses breast cancer progression by targeting metadherin[J].Oncotarget,2016,7(2):1288-1299.
17 张广顺,张光霁,廖广辉,等.藤梨根总三萜化合物通过下调N-Cadherin、Snail抑制BGC-823胃癌细胞侵袭的体内外实验研究[J].中华中医药杂志,2016,31(4):1188-1192.
18 陈永杰,史仁杰.藤梨根提取物对大肠癌LoVo细胞增殖的抑制作用及诱导凋亡的影响[J].世界华人消化杂志,2012,20(18):1657-1661.
19 胡兵,沈克平,史秀峰,等.藤梨根对RKO结肠癌细胞失巢凋亡的作用[J].中国实验方剂学杂志,2013,19(16):242-245.
20 Circu ML,Aw TY.Reactive oxygen species,cellular redox systems,and apoptosis[J].Free Radical Biol Med,2010,48(6):749.
21 Hu WL,Wu CC,Yuan CC,et al.Ethanol extracted from radix of actinidia chinensis inhibits human colon tumor through inhibiting notch-signaling pathway[J].J Cancer,2021,12(3):622-629.
22 Zhou YQ,Zhou ZQ,Li HY,et al.Ethanol extract from radix of actinidia chinensis and evodiamine regulated CCR7 expression in SW480 cells[J].Chin J Mod Med,2011,21(3):336-347.
23 董晶,陆宁,史国军.复方藤梨根制剂联合XELIRI方案治疗结肠癌晚期肝转移的临床研究[J].中国中医药科技,2017,24(2):132-134.
24 国宏莉,李江华,李斌,等.两种藤梨根制剂促凋亡作用的实验研究[J].贵州医药,2013,37(8):675-680.
25 Miliaraki M,Briassoulis P,Ilia S,et al.Survivin and caspases serum protein levels and survivin variants mRNA expression in sepsis[J].Sci Rep,2021,11(1):1-11.
26 王涛,关徐涛,王冰,等.藤梨根提取物通过调控miR-451干预人食管鳞癌EC9706细胞的增殖[J].中国老年学杂志,2019,39(7):1666-1669.
27 Abdi E,Latifi-Navid S,Abdi F,et al.Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers[J].Expert Rev Mol Diagn,2020,20(11):1-19.
28 Khordadmehr M,F Jigari‐Asl,Ezzati H,et al.A comprehensive review on miR‐451:A promising cancer biomarker with therapeutic potential[J].J Cell Physiol,2019,234(12):1-16.
29 党辉,关徐涛,宋锐,等.藤梨根提取物与奥沙利铂在诱导人食管癌细胞Ec9706细胞凋亡中的协同作用[J].中华中医药学刊,2017,35(2):286-289.
30 王冰,关徐涛,王涛,等.基于藤梨根提取物调控miR-21干预食管癌细胞Ec9706cDDP的研究[J].时珍国医国药,2015,26(6):1512-1514.
31 Wang Y,Gao XJ,Wei F,et al.Diagnostic and prognostic value of circulating miR-21 for cancer:A systematic review and meta-analysis[J].Gene,2014,533(1):389-397.
32 Pfeffer SR,Yang CH,Pfeffer LM.The role of miR-21 in cancer[J].Drug Dev Res,2015,76(6):270-277.
33 Hou JY,Wang LY,Wu DJ.The root of Actinidia chinensis inhibits hepatocellular carcinomas cells through LAMB3[J].Cell Biol Toxicol,2018,34(4):321-332.
34 He MY,Hou JY,Wang LY,et al.Actinidia chinensis planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9[J].Oncotarget,2017,8(26):42136-42148.
35 Fang TT,Hou JY,He MY,et al.Actinidia chinensis planch root extract(acRoots)inhibits hepatocellular carcinoma progression by inhibiting EP3 expression[J].Cell Biol Toxicol,2016,32(6):1-13.
36 Fang TT,Zhao ZY,Yuan FF,et al.Actinidia chinensis planch root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting the DLX2/TARBP2/JNK/AKT pathway[J].J Ethnopharmacol,2020,251:474-485.
37 邢海洋,张砚迪,王可心,等.中华猕猴桃根提取物对肝癌细胞Bel-7402的放疗增敏作用[J].实用临床医药杂志,2020,24(7):62-64.
38 马慧利,任中海,李明林,等.藤梨根提取物通过微小RNA-34-5p调控肝癌细胞生物学行为[J].中华实验外科杂志,2019(10):1762-1765.
39 关英,阿选德.藤梨根乙酸乙酯提取物对肺癌A549细胞凋亡的诱导作用[J].中国药房,2015,26(25):3499-3501.
40 袁古治.藤梨根水提取物对人肺癌细胞增殖抑制的影响[J].中医临床研究,2019,11(10):34-36.
41 Wang LY,Hou JY,Shi L.Inhibitory effects of actinidia chinensis planch root extracts(acRoots)on human lung cancer cells through retinoic acid receptor beta[J].Int J Green Nanotechnol,2017,5(2):1-12.
42 Lv JP,Wang LY,Shen H,et al.Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract(acRoots)[J].Cell Biol Toxicol,2018,34(3):207-218.
43 Wang LY,Hou JY,Wang JX,et al.Regulatory roles of HSPA6 in Actinidia chinensis Planch.root extract(acRoots)‐inhibited lung cancer proliferation[J].Clin Transl Med,2020,10(2):1-12.
44 杨誉佳,陆远富,安强,等.藤梨根提取物对宫颈癌的抑制作用[J].中华中医药学刊,2019,37(7):1710-1714.
45 雷蕾.藤梨瞿芪方对人卵巢癌SKOV-3细胞增殖和凋亡的影响[D].宁夏:宁夏医科大学,2020.
46 Liu B,Cui J,Sun J,et al.Immunolocalization of MMP9 and MMP2 in osteolytic metastasis originating from MDA-MB-231 human breast cancer cells[J].Mol Med Rep,2016,14(2):1099-1106.

[1]	马悦, 马志刚, 于杨, 郑桐森, 张艳桥, 张纯慧. 新型冠状病毒肺炎疫情期间抗肿瘤药物临床试验的管理[J]. 实用肿瘤学杂志, 2020, 34(2): 103-106.
[2]	许健, 詹月萍, 蒋元烨, 曹勤. α-常春藤皂苷的抗肿瘤药理作用研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 553-556.
[3]	王吉锡, 邓伟生, 王凤儒, 史之茂, 孟丹, 徐强, 张玉瑶. 甘草提取物的有效部位诱导人宫颈癌HeLa细胞株凋亡及对凋亡相关蛋白Caspase-3和Caspase-9表达的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 390-395.
[4]	于婧璐综述, 冯晓玲审校. 桦褐孔菌抗肿瘤机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 69-72.
[5]	陈玥琦, 刘毅敏, 张定林. 转铁蛋白-转铁蛋白受体抗肿瘤作用研究进展[J]. 实用肿瘤学杂志, 2015, 29(1): 65-68.
[6]	孔洁羽, 李胜棉. 原发性肝癌TACE术中常用抗肿瘤药物的疗效评价[J]. 实用肿瘤学杂志, 2015, 29(1): 82-85.
[7]	马维娜,郁萍综述,孟拥军审校. 多肽作为抗肿瘤药物载体的研究进展[J]. 实用肿瘤学杂志, 2014, 28(5): 465-468.
[8]	陈建国李金霞,综述程池?审校. 诺尼抗肿瘤作用及其机制的研究进展[J]. 实用肿瘤学杂志, 2014, 28(4): 349-353.
[9]	张利祥, 刘毅敏, 赵先英综述, 张定林审校. 白藜芦醇抗肿瘤作用及机理研究进展[J]. 实用肿瘤学杂志, 2013, 27(4): 377-380.
[10]	高海建, 许尤琪. 中药治疗胃癌的机制研究进展[J]. 实用肿瘤学杂志, 2012, 26(2): 162-167.
[11]	彭芳, 陈明. 放疗联合分子靶向药物治疗非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2012, 26(1): 42-48.
[12]	张宏伟, 陈洪生, 刘明. 鞣花单宁多靶点治疗恶性肿瘤[J]. 实用肿瘤学杂志, 2011, 25(4): 396-400.
[13]	杨悦, 姬宏飞, 王波, 安巍巍. 红松松塔加压热提取物对S180荷瘤小鼠肿瘤生长及胸腺、脾指数的影响[J]. 实用肿瘤学杂志, 2011, 25(3): 212-214.
[14]	王萌, 陈公琰, 洪璇, 杨朝阳. 重组人血管内皮抑素联合顺铂治疗恶性胸腹腔积液的临床观察[J]. 实用肿瘤学杂志, 2011, 25(1): 53-56.
[15]	徐亚辉, 综述, 汪宏波, 王泽华, 审校. 趋化因子Fractalkine在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2009, 23(4): 371-374.

藤梨根抗肿瘤药效物质和药理活性研究进展

Research progress on antitumor medicinal substances and pharmacological activities of Radix Actinidia chinensis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价